February 11, 2009 2:37 PM
- Text
AIDS Vaccine Trial Scaled Back
(AP)
Plans for a large-scale trial of a potential AIDS vaccine are being dropped in favor of a smaller, more focused study, the National Institutes of Health said Thursday.
The trial of the vaccine, developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease, had been planned to include 2,400 men in the United States in a study called PAVE 100.
However, the agency said that it decided that the vaccine did not warrant a trial of this size and scope. Instead NIAID said it will plan a smaller, more focused clinical trial designed to see whether the product has a significant effect on the amount of virus in a person's blood.
If an effect is found, then additional studies, or an expansion of the study could be carried out.
NIAID said it acted after reviewing the results of the STEP trial, a study of another vaccine that was halted last fall after reports of an increased number of infections among volunteers taking part in the test.
The agency said it still considers its vaccine scientifically intriguing and sufficiently different from other vaccines to proceed with the smaller trial.
The trial of the vaccine, developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Disease, had been planned to include 2,400 men in the United States in a study called PAVE 100.
However, the agency said that it decided that the vaccine did not warrant a trial of this size and scope. Instead NIAID said it will plan a smaller, more focused clinical trial designed to see whether the product has a significant effect on the amount of virus in a person's blood.
If an effect is found, then additional studies, or an expansion of the study could be carried out.
NIAID said it acted after reviewing the results of the STEP trial, a study of another vaccine that was halted last fall after reports of an increased number of infections among volunteers taking part in the test.
The agency said it still considers its vaccine scientifically intriguing and sufficiently different from other vaccines to proceed with the smaller trial.
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Marijuana-smoking motorists twice as likely to crash
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Things You Didn't Know About Your Penis
- Norovirus outbreak hits Rider University in N.J
- John Dye Dies: What Killed "Angel" Star?
- PICTURES: 15 Shocking Sexual Fetishes
- America's sodium problem: Not from salty snacks?
- America's pets also have an obesity epidemic
- Caffeine inhalers - the next club drug?
- Let's Move! campaign turns 2 today: Is it working?
- Chinese mom gives birth to 15-pound baby
- Woman spotlights uterus didelphys on talk show
- HealthPop: Online dating and jaw engraving
- Christina Hendricks: Too Big for Hollywood?
- 8 Tips For Losing Weight After Pregnancy
Latest CBS News Headlines
on Facebook
on CBS News
- UK gov't: Press must face tougher penalties
- Bahrain's ailing Gulf Air secures $80 million loan
- Pop queen Whitney Houston dies at age 48
- Pop queen Whitney Houston dies on eve of Grammys
on Facebook
- Whitney Houston 1963-2012
- Adele sings a cappella for Anderson Cooper
- Remembering Whitney Houston 1963-2012
on CBS News






